A recent perspective article published in Cell Press’ Stem Cell Reports highlights the potential of leveraging the microgravity environment of low-Earth orbit for biomanufacturing and regenerative medicine. Co-authored by Redwire and Redwire’s SpaceMD Chief Scientist, Dr. Ken Savin, the article brings together research from leading space and research organizations to discuss the latest breakthroughs in stem cell therapies, disease modeling and automation and how strategic partnerships and policy support will be crucial for the future of this burgeoning sector.

Redwire is a leader in microgravity research and development technologies, having flown hundreds of experiments to space. Redwire’s microgravity technology enables space biotechnology and pharmaceutical development, helping companies unlock new insights for potential therapeutics and paving the way for microgravity research on future commercial space stations.

Find out more about the transformative power of microgravity for the benefit of human health in the article here: Biomanufacturing in low Earth orbit: A paradigm shift